Sitemap
- Immunoglobulin Access
- Mainmenu
- Membership Menu
- Plasma Products Database Menu
- Media and Information Menu
- Advocacy Menu
- Uncategorized
- Plasma Protein Therapies
- Quality and Standards
- Meetings and Events
- PPTA Business Forum
- Regulatory Policy
- Regions
- Current Members
- Plasma Products Database
- Media and Information
- Press Releases
- A missed opportunity to acknowledge EU’s dependency on U.S. plasma
- International Plasma Awareness Week 2022: Donate Locally. Think Globally.
- Adoption of the EP report “EU Pharmaceutical Strategy”
- Calling on EU Policymakers to Increase Plasma Donations
- International Plasma Awareness Week 2021: Donate Plasma. Save Lives.
- EU Health Commissioner says plasma donation plays a vital role
- Lifting of long-time ban on use of UK plasma for manufacturing of immunoglobulins will help patients
- Treatments for rare diseases at risk, due to the decline of plasma donations
- Inception Impact Assessment Underlines the Need for Timely Action to Decrease the Reliance on Third Countries for Plasma
- International Plasma Awareness Week 2020: Be a Hero, Donate Plasma Today
- EU Health Commissioner Says Plasma Donation is “More Important Than Ever”
- New Edition of EDQM Blood Guide Risks Decreasing European Plasma Collection
- PPTA Applauds Administration for Focus on Plasma Donation
- Plasma-Derived Therapies Provide Significant Health Value Gain
- PPTA encourages EDQM to take a patient-centric approach in the implementation of its Plasma Supply Management Recommendations
- PPTA Welcomes New Executive Director of European Division
- PPTA Names Amy Efantis President & CEO
- PPTA Recognizes Essential Contributions of Plasma Donors
- GLOBAL INITIATIVE DRAWS ATTENTION TO RARE DISEASE TREATMENTS
- Rep. Matsui Recognizes International Plasma Awareness Week
- International Plasma Awareness Week: Plasma Donors are the Foundation
- David Bell Elected Chair of PPTA Global Board of Directors
- Patient Organizations and Industry Join Together to Celebrate Third Annual International Plasma Awareness Week
- PPTA Celebrates International Plasma Awareness Week
- Alabama Lowers Minimum Donation Age to 18
- PPTA Recognizes World Hemophilia Day–April 17, 2015
- PPTA Recognizes 8th Annual International Rare Disease Day
- Ensuring Access to Medicines for Patients: Pharmaceutical Industry Associations Release ‘Principles for Communication of Information on Quality and Manufacturing Potential Supply Disruption’
- International Plasma Awareness Week to Celebrate Donors and Spotlight Rare Diseases
- PPTA Recognizes World Hemophilia Day 2014
- PPTA Recognizes First Plasma Collection Centers Certified in Hungary
- PPTA Letter to Stakeholders re: European Data Program Update
- PPTA Letter to Stakeholders re: European Data Program
- Plasma Protein Therapeutics Industry to Convene in Denver
- Patient Organizations Join Forces with Industry
- Industry, Donors and Patients to Convene in Vienna
- Plasma Donors and Rare Diseases Take Center Stage
- PPTA Staff Honored with the Distinguished Alumni Award
- PPTA Applauds Preserving Access to Orphan Drugs Acts
- Discoveries and Developments: Highlights of the Plasma Protein Forum (June 2013)
- PPTA and Member Companies Demonstrate Sustained Commitment to Patient Safety (June 26, 2013)
- PPTA and Six Organizations Oppose NJ Tax on Clotting Factor (June 27, 2013)
- PPTA Recognizes World Hemophilia Day
- PPTA Statement: Effects of Sequester on Plasma Protein Therapies
- PPTA Recognizes International Rare Disease Day 2013
- Kedrion CEO Assumes Board Helm of PPTA
- PPTA applauds the House of Representatives for Passing Milestone IVIG Access Act
- Plasma Collection Continues to Gain Traction in Czech Republic
- PPTA Presents at the European Haemophilia Consortium
- PPTA Presents at ESID 2012
- PPTA's 2012 Plasma Protein Forum
- Celebrating PPTA's 20th Anniversary
- First Internationally Certified Plasma Collection Center in Czech Republic
- In Memoriam of Dr. Otto Schwarz
- PPTA Honored in House of Representatives
- PPTA Comments to FDA
- PPTA Recognizes World Hemophilia Day
- PPTA Recognizes International Rare Disease Day 2012
- PPTA Letter to Stakeholders re: North America Data Program
- PPTA Letter to Stakeholders re: North America Data Program
- California State Assemblymember Atkins Honored At PPTA's Business Forum
- PPTA Attends FDA Public Workshop on Drug Shortages
- Californians And Floridians Recognized For Role In Helping Rare Disease Patients Who Need Lifesaving Therapies
- ConQuaestor Report Confirms Cross Subsidies Within Sanquin
- IRS Proposed Regulations on Orphan Drug Exclusion from Drug Tax Stand to Harm Future Development of Treatments for Rare Disease Patients
- PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
- PPTA Praises Legislation that Protects the Treatment of Rare Diseases
- PPTA Opposes Tax on Blood Clotting Factor
- PPTA Industry Expert Invited To Serve On HHS Advisory Committee On Blood Safety And Availability
- PPTA Hosts Discussion Forum on Blood/Plasma Products in The Hague
- PPTA Applauds the Florida Legislature for Preserving Medicaid Patient Access to Blood Clotting Factor
- PPTA Commends Congress and President Obama for Repealing the 1099 Tax-reporting Provision
- New Spanish Language Translations Available on PPTA Websites
- PPTA Hosts Congressional Staff Briefing
- PPTA Statement: Proven Safety of Human Albumin
- Patient Organizations and Industry Join Together to Celebrate Fourth Annual International Plasma Awareness Week
- Statements
- PPTA Statements
- PPTA Statement on the Ukraine Crisis
- PPTA Leadership Update – Amy Efantis
- PPTA Disagrees with Ruling from Romanian Competition Council
- Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
- New position statement by CHMP regarding donor deferral criteria for sexual behaviour helps assessment of PMFs
- Study Shows Immunoglobulin Therapy is “Critical and Cost-Effective” in Treating CVID
- PPTA Responds to ProPublica Article
- Human Plasma Donations Remain Important During COVID-19 Pandemic
- PPTA Statement on Immunoglobulin Use to Meet Clinical Need
- PPTA Statement on the Inauguration of President Biden
- Yes, you can donate source plasma after getting the COVID vaccine
- PPTA Statement on Alberta’s Passing of the Voluntary Blood Donation Repeal Act
- PPTA Statement on the Urgent Need for Plasma Donation
- Plasma Donors Should be Celebrated, not Denigrated
- New York and California recognize the importance of plasma donation
- PPTA Testifies at USITC COVID-19 Related Goods Hearing
- PPTA Opposes Executive Order That Would Threaten Access to Plasma Protein Therapies
- PPTA Repeats Appeals for Plasma Donations
- White House Roundtable: “We’re in this Together”
- PPTA Responds to July 24 White House Executive Orders
- Wall Street Journal: Letter to the Editor
- PPTA Encourages Plasma Donation
- PPTA Reacts to Huffington Post Article
- PPTA Statement on FDA Guidance Documents
- PPTA Responds to The Guardian Article
- Letter to CMS to Allow Home Infusion COVID
- A Note to European Plasma Donors on the Spread of Coronavirus
- PPTA Responds to ARD Documentary
- A Note to U.S. Plasma Donors on the Spread of Coronavirus
- New Coronavirus (SARS-CoV-2) and the Safety Margins of Plasma Protein Therapies
- PPTA Statement on H.R. 3
- PPTA Responds to Newsweek Article
- PPTA Responds to New York Times Article
- PPTA Comments on Time Magazine Article
- Statement on Romanian Competition Council
- Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA)
- PPTA Statement on “How Blood-Plasma Companies Target the Poorest Americans”
- Plasma protein product safety and Creutzfeldt-Jakob disease (CJD)
- Statement from Jan M. Bult, President & CEO, Plasma Protein Therapeutics Association
- PPTA is Proud to Support Rare Disease Day 2017
- PPTA Statement on the Documentary “Das Geschäft mit dem Blut”
- PPTA Recognizes World PI Week: April 22-29, 2016
- PPTA Recognizes World Hemophilia Day–April 17, 2016
- FDA Releases Final Guidance on MSM Deferral Policy
- PPTA Letter to Stakeholders re: North America Data Program
- PPTA Letter to Stakeholders re: European Data Program Update
- PPTA Statement on Review of Donor Blood Pressure Requirements
- PPTA Statement on Review of Donor Weight Loss Monitoring
- PPTA Statement on Management of Donors and Units that Test Positive for Hepatitis B Virus (HBV) DNA by Nucleic Acid Tests (NAT)
- PPTA Statement on Current Considerations on Plasma Obtained from Whole Blood Donors for Further Manufacturing Use
- Statement on Update on Safety of Albumin
- PPTA Stat ement on the Rare Bleeding Disorders Workshop
- PPTA Statement on Clinical and Surrogate Endpoints for Evaluating Efficacy of Alpha 1-Proteinase Inhibitor (Human) Augmentation Therapy
- Dengue Virus and Plasma Protein Therapies
- Human Parvovirus PARV4 and plasma protein therapies
- Citrate Anticoagulant and Apheresis Perspective of Plasma Protein Therapeutics Industry
- PPTA Statement on Safety of Plasma Protein Therapies and the H5N1 Virus es
- Statement on the Safety of Plasma Protein Therapies and Swine Influenza Virus
- PPTA Statement on MSM Donor Policy
- PPTA Statement: Effects of Sequester on Plasma Protein Therapies
- PPTA Statement: Proven Safety of Human Albumin
- PPTA Comments on the IQWiG Rapid Report on Haemophilia Therapies
- PPTA Statement on Signing of Health Care Reform Bill
- Ebola Virus and Plasma Protein Therapies
- PPTA's Updated Response to Ontario's Proposal to Ban Compensated Plasma Donation
- Zika Virus and Plasma Protein Therapies
- Access to Care
- European Plasma Alliance
- FAQs: Source and Recovered COVID-19 Plasma Donors are Essential
- Novel Coronavirus Disease (COVID-19) Resources
- Immunoglobulin Access Materials
- Access to Care | U.S. State
- Access to Care | U.S. Federal
- A propos de PPTA France
- Donor Stories
- Patient Stories
- United Kingdom
- The Netherlands
- Germany
- Belgium
- Austria
- Access to Care | Europe
- News
- PPTA News
- Extension of EU/US MRA to Include PDMPs Is a Positive Step Forward
- HHS Launches Plasma and Blood Donation Campaign
- PPTA Statement on the draft EU Substances of Human Origin Regulation
- Monkeypox Virus and Plasma Protein Therapies
- Announcing PPTA’s New Global Chair
- PPTA's 2021 Annual Report Now Available
- The Telegraph continues maligning plasma donors
- Transfusion publishes scientific paper regarding viral safety of plasma-derived therapeutics
- Fabrizio Fabbrizzi – 10 April 1955 - 2 January 2020
- PPTA Letter to American National Red Cross
- PPTA Statement on Immunoglobulin Access
- Immunoglobulin Access
- PPTA Highlights Importance of Patient Access to Plasma Protein Therapies
- Donor ethics letter submitted to the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada
- PPTA Responds to The Pharmaceutical Journal
- PPTA is concerned that the U.S. Senate is considering legislation that would move control over essential health benefits to all 50 states
- The U.S. Senate will try to move forward shortly on a “motion to proceed” to debate on repeal of the Affordable Care Act
- Endangering Patient's Access to Care: Proposals to Repeal the Affordable Care Act
- PPTA Proudly Supports World Hemophilia Day 2017
- The Hilfenhaus Award conferred to Prof. Farkas at the IPPC 2017
- PPTA Remembers John W. Walsh
- PPTA Remembers Corey Dubin
- PPTA Supports 9th Annual International Rare Disease Day
- Vale - Guelfo Marcucci – Father of Italian fractionation
- New Study Shows Increased Development of Inhibitors using Recombinant Factor VIII
- New Supplement Addresses Hemolytic Complications of IVIG Infusions
- PPTA Mourns Passing of Dr. Víctor Grífols Lucas
- Initiation of the Five Week Enrollment Period for the Medicare IVIG Demonstration Project
- EHC Video on European Recommendations for Haemophilia Treatment
- Restrictive Coverage Policies and Patient Access
- Vaccine Recommendations for Patients with PI
- PPTA Announcement: DLA Piper to Provide Federal Legislative Representation
- PPTA's Response to Ontario's Proposal to Ban Compensated Plasma Donation
- IN MEMORIAM: MENSO BULT
- Rare Disease Day Congressional Tele-Town Hall
- IN MEMORIAM THEO EVERS
- PPTA Recognizes International Rare Disease Day 2014
- PPTA Strengthens Global Brand
- FDA Request to Cease Blood Collection in Florida
- Ethical Considerations in Compensated Plasma Donation
- PPTA Chosen to Join Mission to China
- Source Plasma News
- Regulatory Policy News
- Final Summary of the PPTA/FDA Liaison Meeting on September 14, 2022
- Final Summary of the PPTA-FDA Liaison Meeting: October 7, 2021
- PPTA Works with Federal Regulators in the U.S.
- Final Summary FDA Liaison Meeting: November 18, 2020
- Public Workshop Focuses on Immune Globulin Products
- FDA Posts Public Meeting Documents
- 115th meeting of the FDA Blood Products Advisory Committee
- PPTA Presents at ACBTSA Meeting
- PPTA Attends the 114th Meeting of the FDA Blood Products Advisory Committee (BPAC)
- BPAC Meets to Hear Research Program Updates
- PPTA Co-Sponsors Public Workshop
- PPTA Staff Honored with the Distinguished Alumni Award
- FDA Launches New Quality/Compliance Web Content
- PPTA Participates in Health Canada Roundtable
- FDA Announces Meeting Date: Blood Products Advisory Committee
- Meetings and Events News
- Patient Access News
- Global Access News
- Free Trade News
- PlasmaLit Database Updates
- Distribution Data
Media and Information
Copyright © 2022 PPTA. All rights reserved. (202) 789-3100